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MAIN TEXT 1
Intellectual disability (ID) and other neurodevelopmental disorders are in part due to de novo mutations 2 affecting protein-coding genes. [1] [2] [3] [4] Large scale exome sequencing studies of patient-parent trios have 3 efficiently identified genes enriched for de novo mutations in cohorts of individuals with ID compared to 4 controls, 2 or based on expected gene-specific mutation rates. 5 
5
Here we sequenced the exomes of 820 patients with intellectual disability and their parents as part of 6 routine genetic testing at the RadboudUMC in the Netherlands. We identified 1,083 de novo mutations 7
(DNMs) in the coding and canonical splice site regions affecting 915 genes ( Supplementary Tables 1-2,  8 Supplementary Figures 1-4) . In our cohort we detected an increased number of Loss-of-function (LoF) 9 mutations compared to controls (Fisher's exact test p=9.38x10 -12 , Supplementary Methods), and 10 enrichment for recurrent gene mutations (observed vs. expected, p<1×10 -5 , Supplementary Figure 5 ). 11
Based on an established framework of gene specific mutation rates 6 , we calculated for each gene the 12 probability of identifying the observed number of LoF or functional DNMs in our cohort ( Supplementary  13 Methods). To validate this approach we first performed the analysis on the complete set of 820 ID 14 patients. After Benjamini-Hochberg correction for multiple testing, 18 well-known ID genes were 15 significantly enriched for DNMs ( Supplementary Table 3 and 4) . To optimize our analysis for the 16 identification of novel candidate genes in the RUMC cohort, we removed all individuals with mutations 17
in any of the known ID genes (Supplementary Methods, Supplementary Figure 6 ). Repeating the 18 analysis for mutation enrichment, we identified 4 genes (DLG4, PPM1D, SOX5, TCF20) not previously 19 associated with ID to be significantly enriched for DNMs in our cohort (Figure 1, Table 1 , Supplementary 20 Table 5 ). To achieve the best possible power for the identification of novel candidate ID genes, we next 21 added data from 4 previously published family-based sequencing studies ( Supplementary Table 1 ). The 22 combined cohort included 2,104 trios and 2,637 DNMs across 1,990 genes. After again excluding 23 individuals with mutations in known ID genes, this cohort consisted of 1,471 individuals with 1,400 24 DNMs in 1,235 genes (Supplementary Methods, Supplementary Figure 6 ). Meta-analysis on this 25 combined cohort identified 10 novel candidate ID genes with more LoF, or more functional, DNMs than 26 expected a priori. These 10 genes included the four novel candidate ID genes previously identified in the 27 RUMC cohort, as well as RAC1, SMAD6, SON, TLK2, TRIP12 and SYNCRIP (Figure 1 , Table 1 , 28
Supplementary Table 6 ). 29
To further evaluate the identification of the 10 novel candidate ID genes, we compared the phenotypes 30 of the 18 RUMC individuals with DNMs in these genes. We observed strong phenotypic overlap for some 31 of these genes (Figure 2 , Supplemental case reports, Supplementary Table 7 ). Further genes, such as 32 SETD2, which are close to statistical significance, show phenotypic similarities suggestive for a shared 33 genetic cause consistent with previous case reports 7, 8 (Supplementary Figure 7 , Supplemental Case 34 reports). 35 36 Studies have shown that genes involved in genetic disorders exhibit strongly reduced tolerance to 37 genetic non-synonymous variation compared to non-disease genes. This is particularly evident for ID. 3 
38
We found that a large set of well-known dominant ID genes (n=444), as well as the 10 novel candidate 1 ID genes are highly intolerant to LoF variation 9 (Median pLI of 0.95; p<1x10 -5 and 0.99 ; p<1x10 -5 2 respectively; Supplementary Methods, Supplementary Figure 8 and Supplementary Table 8 ). 3 Intriguingly, we noted that those known and novel candidate dominant ID genes that harbor only 4 missense variants are among the most intolerant ID genes (Median pLI of 0.99; p<1x10 -5 ; 5
Supplementary Figure 8) . Additionally, we find that mutations in 'missense only' genes are more likely 6 to cluster than mutations in genes for which we also identified LoF mutations (p=0.01, Fisher's exact 7 test; Supplementary Methods, Supplementary Table 9 ). 8 There is considerable overlap of genes and molecular pathways involved in neurodevelopmental 9
disorders (NDDs) such as autism spectrum disorder (ASD), schizophrenia (SCZ), epileptic encephalopathy 10 (EE) and ID. 10 Therefore we performed a third analysis including 12 published family-based sequencing 11 studies of various NDDs (Supplementary Table 1, Supplementary Figure 6 ). Repeating our analysis in 12 this NDD cohort, we identified 7 genes significantly enriched for either LoF or functional DNMs 13 ( Supplementary Figure 9 , Supplementary Table 10 ). In line with our hypothesis, five of the identified 14 genes were also identified in our previous analyses with individuals with ID only, whereas two genes 15 (SLC6A1 and TCF7L2) only reached significance in the NDD meta-analysis due to additional mutations in 16 patients with other phenotypes than ID ( Supplementary Table 11 ). In more detail, for two of the five 17 candidate ID genes (TLK2 and TRIP12) additional de novo mutations were identified in individuals with 18 ASD and SCZ, suggesting that DNMs in these genes may lead to a broader phenotype than only ID. For 19
TRIP12, a similarly broad phenotype has been reported previously. 4 20 In summary, we identified 10 novel candidate ID genes in a meta-analysis of WES data on 2,104 ID trios. 21 The statistical framework used here, differs from existing methods based on gene specific mutation 22 rates, by removing all trios with mutations in known disease genes, and by applying Benjamini-Hochberg 23 correction for multiple testing. Our study underscores the impact of de novo mutations on a continuum 24 of neurodevelopmental phenotypes, that impinge on a broad range of processes including chromatin 25 modifiers (TRIP12, TLK2), FMRP target and synaptic plasticity genes (DLG4; Supplementary Figure 10) 26 and embryonically expressed genes (PPM1D, RAC1) 2 . Data from a similar systematic study of de novo 27 mutations in neurodevelopmental disorders suggest that many, and possibly most, genes causing severe 28 developmental disorders by de novo mutation are now known 11 . Yet, only TCF20 and PPM1D are shared 29 between the 10 novel genes in our study and the 14 Competing financial interests 17 The authors declare no competing financial interests. 18
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Plasma membrane-associated small GTPase involved in many cellular processes. In the synapses, it mediates the regulation of F-actin cluster formation by SHANK3. 
Recruitment of individuals with ID 2
The Department of Human Genetics from the Radboud University Medical Center (RUMC) is a tertiary 3 referral center for clinical genetics. Approximately 350 individuals with unexplained intellectual disability 4 (ID) are referred annually to our clinic for diagnostic evaluation. Since September 2011 whole exome 5 sequencing (WES) is part the routine diagnostic work-up aimed at the identification of the genetic cause 6 underlying disease. 12 For individuals with unexplained ID, a family-based WES approach is used which 7 allows the identification of de novo mutations as well as variants segregating according to other types of 8
inheritance, including recessive mutations and maternally inherited X-linked recessive mutations in 9
males. 13 For the purpose of this study, we selected all individuals with ID who had family-based WES 10
using the Agilent SureSelect v4 enrichment kit combined with sequencing on the Illumina HiSeq platform 11 in the time period 2013-2015. This selection yielded a set of 820 individuals, including 359 females and 12 461 males. The level of ID ranged between mild (IQ 50-70) and severe-profound (IQ<30). 13
Families gave informed consent for both the diagnostic procedure as well as for forthcoming research 14 that could result in the identification of new genes underlying ID by meta-analysis, as presented here. 15 Explicit consent for photo-publication was sought and given by a subset of families. 16
Diagnostic whole exome sequencing 17
The exomes of 820 patient-parent trios were sequenced using DNA isolated from blood, at the Beijing 18
Genomics Institute (BGI) in Copenhagen. Exome capture was performed using Agilent SureSelect v4 and 19 samples were sequenced on an Illumina HiSeq instrument with 101bp paired-end reads to a median 20 coverage of 75x. Sequence reads were aligned to the hg19 reference genome using BWA version 0.5.9-21 r16. Variants were subsequently called by the GATK unified genotyper (version 3.2-2) and annotated 22
using a custom diagnostic annotation pipeline. Base-pair resolution coverage of the regions enriched by 23 the SureSelect V4 kit are computed by BEDTools based on the regions as provided by the manufacturer. 24
An average 98.9% of Agilent SureSelect V4 enriched targets was covered by 10 or more reads for the 25 RUMC cohort of 820 ID patients (Supplementary Figure 1) . 26
Identification of de novo mutations in 820 individuals with ID 27
The diagnostic WES process as outlined above only reports (de novo) variants that can be linked to the 28 individuals' phenotype. In this study, we systematically collected all de novo mutations located in coding 29 sequence (RefSeq) and/or affected canonical splice sites (canonical dinucleotides GT and AG for donor 30 and acceptor sites; Supplementary Figure 4 ), identified in 820 individuals with ID irrespective of their 31 link to disease, to evaluate the potential relevance of genes for ID in an unbiased fashion using a 32 statistical framework. De novo mutations were called as described previously. 13 Briefly, variants called 33 within parental samples were removed from the variants called in the child. For the remaining variants 34 pileups were generated from the alignments of the child and both parents. Based on pileup results 35 variants were then classified into the following categories: "maternal (for identified in the mother 36 only)", "paternal (for identified in the father only)", "low coverage" (for insufficient read depth in either 37 parent), "shared" (for identified in both parents)", and "possibly de novo" (for absent in the parents). 1
Variants classified as "possibly de novo" were included in this study. 2
We applied various quality measures to ensure that only the most reliable calls were included in the 3 study: (i) all samples had less than 25 "possibly de novo" calls; (ii) the variant had at least 10x coverage 4 in either parent (e.g. high prior probability of being inherited); (iii) the location was not known in dbSNP 5
version137 (e.g. possible highly mutable genomic location) and (iv) was identified in a maximum of 5 6 samples in our in-house variant database (e.g. eliminating variants that are too frequent to be disease-7
causing given the incidence of ID in combination with the sample size of our in-house database); and (v) 8 each variant showed a variant read percentage >30%, or alternatively, >20% with >10 individual variant 9 reads and (vi) a GATK quality score of >400. For de novo variants called within a 5bp window of each 10 other within the same individual, variant calls were manually curated and merged into a single call 11
(when occurring on the same allele). This set of criteria resulted in the identification of 1,083 potential 12
de novo mutations in 820 individuals with ID. 13
Validation and categorization of de novo mutations 14
In a separate (unpublished) in-house study, we recently determined the predictive value for GATK 15 quality scores in terms of the variant being validated by Sanger sequencing. A set of 840 variants called 16 by the same version of GATK was retrospectively analyzed for their respective quality scores and 17 validation status. Based on this assessment, we determined that a GATK quality score ≥500 resulted in 18
100% of variants being validated by Sanger sequencing (data not shown; internal reference VAL G 084). 19 In addition to our in-house study two other studies also found a 100% Sanger validation rate for the 20 variants with a GATK quality score of ≥500. 14 Based on this we considered all variants with a GATK Q-21 score of ≥500 (n=1,039) to be true de novo mutations. Nonetheless, a random set of 141 potential de 22
novo mutations with GATK Q-scores of ≥500 were all confirmed by Sanger sequencing. All potential de 23
novo variants with a GATK Q-score between 400-500 (n=40) were subsequently validated by Sanger 24 sequencing, and all were confirmed. All 20 de novo mutations of the reported novel candidate genes 25
were confirmed by Sanger sequencing (Supplementary Table 2 , Supplementary Figures 2-4) . and all missense mutations (n=638) (Supplementary Figure 4) . For variants within the same individual 31 and within the same gene but more than 5bp apart, the variant with the most severe functional effect 32 was considered for the per gene statistics (see below). 33
Evaluating the number of recurrently LoF and functional de novo mutated genes 34
We simulated the expected number of recurrently mutated genes by redistributing the observed 35
number of mutations at random over all genes based on their specific loss-of-function (LoF, see section 36
"Statistical enrichment of DNMs") and functional mutation rates (see section "Statistical enrichment of 37 DNMs") as described by Samocha et al. 6 Based on 100,000 simulations we calculated how many times 38 the number of recurrently mutated genes was the same or exceeded the observed number of 1 recurrently mutated genes in the RUMC dataset. We performed the simulation separately for LoF and 2
functional DNMs (Supplementary Figure 5) . P-values were then calculated by taking the number of 3 times the number of recurrently mutated genes exceeded the observed number of recurrently mutated 4 genes, divided by the number of simulations. 5
Genes previously implicated in ID etiology 6
To evaluate whether the genes identified by our meta-analyses have been implicated in ID before, two 7
publicly available repositories of genes known to be involved in ID were used. Firstly, we used our list of 8 707 genes, routinely used by our diagnostic setting to interpret WES results of individuals with ID. 15 9 Secondly, we downloaded a list of 1,424 genes from the DDG2P database reflecting genes to be 10 associated with developmental disorders, which has been compiled and curated by clinicians as part of 11
the DDD study to facilitate clinical feedback of likely causal variants. 5 In total the two lists compromised 12 1,537 unique genes. In this manuscript, the list of unique gene entries is referred to as known ID genes 13
( Supplementary Table 4 ). 14
Statistical enrichment of DNMs 15
In our meta-analysis for ID and neurodevelopmental disorders we only included studies with minimum 16 of 50 trios. For each gene, and each of the functional classes (LoF and functional) ,we used the 17 corresponding gene specific mutation rate (GSMR) as published by Samocha et al. (2014) 6 to calculate 18 the probability of the number of identified de novo mutations in our cohort. For genes for which no 19 GSMR was reported, we used the maximum GSMR of all reported genes (i.e. the GSMR of the gene TTN). 20 We then calculated specific mutation rates for the two defined functional classes (loss-of-function, 21 functional). The GSMR for loss-of-function DNMs was calculated by summing the individual GSMR for 22 nonsense, splice site and frame-shift variants; The GSMR for functional DNMs was calculated by 23 summing the GSMR for the loss-of-function (LoF) variants with the missense mutation rate; and for 24 genes for which variants from different functional classes were identified, we used the overall GSMR. 25
For the stoploss and startloss mutations we used the LoF-rate and for in-frame indels the functional 26 rate. Null hypothesis testing was done using a one-sided exact Poisson Test based on a sample size of 27 820 individuals with ID, representing 1,640 alleles for autosomal genes, and 1,179 alleles for genes on 28 the X-chromosome (461 males). 29
For DNMs on chromosome X the correct mutation rate depends on the patient's gender as the mutation 30 rates for fathers is higher than for mothers. Estimates show a 4:1 ratio of paternal to maternal de novo 31 mutations 16 . Hence, male offspring, receiving their chromosome X exclusively from the mother, have 32 therefore a lower mutation rate on chromosome X than estimated by the GSMR. This correction could 33 however only be performed for the RUMC cohort, as information of gender was not available for all 34 studies included in the ID cohort. Of note, not correcting for this bias in male individuals for DNM in 35
genes on the X chromosome, however will lead to less significant p-values for genes on the X-36 chromosome, thereby potentially underestimating the significance of candidate novel ID genes located 37 on the X-chromosome. In the case where one patient has two DNMs in the same gene we ignored one 38 of the two DNMs for the statistical enrichment analysis to avoid false positive results. In the 1 aforementioned case the severity of the DNM protein-effect was used in the choice which DNM to 2 ignore. For example, if a patient has one missense and one nonsense DNM in the same gene the 3 missense mutation was ignored in the statistical analysis. 4
The gene specific p-values were corrected for multiple testing based on the 18,730 genes (present in the 5
Agilent V4 exome enrichment kit) times the number of tests (x2), using the Benjamini-Hochberg 6 procedure with an FDR of 0.05. In our cohort of 820 individuals with ID, conclusive diagnosis were 7
already made based on DNMs in a genes previously implicated in disease. The use of a multiple testing 8
correction with a FDR of 0.05, in combination with a potential large number of DNMs in known ID genes 9 may cause the artificial significance of other genes because of an increasing lenient correction for the 10 least significant genes 17 . To verify that the identification of novel candidate ID genes is not inflated by 11
this effect, we performed the analysis after removing all individuals with a DNM in one of the known 12 genes (potential other DNMs in such individuals were also removed for further analysis). Incidentally, 13
this also increased our statistical power. Figure 6 ). We corrected 20 for testing 34,386 genes (i.e. all 18,730 genes minus the 1,537 known ID genes multiplied by two for 21
testing the loss-of-function and functional categories). 22
Validation of the statistical approach by analysis of DNMs in a control cohort 23
To further confirm the validity of our statistical approach, we applied the same analyses to a set of 24
DNMs identified in trios of healthy individuals and unaffected siblings. Hereto, we downloaded and re-25 annotated all DNMs identified in 1,911 unaffected siblings of individuals with ASD from Iossifov et al. 2 26 together with DNMs in controls ( Supplementary Table 14 ). In total the control set contained 2,019 27 coding DNMs found in 2,299 trios. Of note, the protein coding de novo mutation rate in the control 28 cohort was markedly lower than observed in the individuals with ID (0.91 vs. 1.32, respectively). 29
Additionally, we observed no significant enrichment of recurrently mutated genes for loss-of-function or 30 functional mutations (p=0.60 and p=0.12, respectively, Supplementary Figure 11) . 31
For the control cohort we performed the statistical analysis as described above and identified only one 32 gene to be significantly enriched for DNMs. For YIF1A (FDR corrected p-value = 0.01) we identified a 33 total of 3 missense and 1 frame-shift DNM (Supplementary Table 13-14) . YIF1A may be involved in 34 transport between the endoplasmic reticulum and the Golgi, and has a pLI (probability of being loss-of-35 function intolerant) of 2.08x10 -8 indicating this gene is a loss-of-function tolerant gene .We note that the 36 control cohort consists mostly of healthy siblings from individuals with ASD, and, as such, may still have 37 a small enrichment for mutations that lead to susceptibility for neurodevelopmental disorders. 38
Increased number of Loss-of-function (LoF) mutations in RUMC cohort compared to controls 1
To reduce the impact of the used enrichment kit used in the control set studies and RUMC cohort we 2 computed the intersection of all enrichment kits (Agilent SureSelect 37Mb Agilent SureSelect 50Mb 3
Agilent SureSelect V4 Nimblegen SeqCap V2; see Supplementary Table 12 ) via the ´intersect´ function 4
of BEDTools. Only the loss-of-function de novo mutations present in the 28,189,737 Mb intersection of 5 the four enrichment kits were used in the analysis. The Fisher's exact test on the enrichment kits 6
normalized loss-of-function de novo mutations yielded a significant difference with p-value= 9.38x10 -12 7
(RUMC: 157 LoF de novo mutations of a total of 805 de novo mutations; control set: 137 LoF de novo 8 mutations of a total of 1,485 de novo mutations). The coverage and other relevant technical information 9
of the control studies are enlisted in Supplementary table 12. We note it is important to take into 10 account the coverage and false negative rates of all sequencing studies. So far, only a single study has 11
attempted to provide a false negative rate (e.g. mutations that are there but were not identified) for 12 exome sequencing, and this was predicted to be <5% 2 . 13
Attributing pLI for all protein coding genes 14
To determine the intolerance to loss-of-function (LoF) variation for each gene, we used the pLI which is 15 based on data from the Exome Aggregation Consortium (ExAC) version 0.3.1 providing exome variants 16 from 60,706 unrelated individuals 9 . The pLI, or the probability of being LoF intolerance, is based on the 17 expected vs. observed variant counts to determine the probability that a gene is intolerant to LoF 18 variants and is computed for a total of 18,226 genes. The closer a pLI is to 1 the more intolerant a gene 19 is to LoF variants. The authors consider a pLI >= 0.9 as an extremely LoF intolerant set of genes. The list 20 of the pLI for the genes used in this study can be found in Supplementary Table 8 . The performance of 21 the pLI was evaluated for four gene sets 1) 170 Loss-of-function (LoF) tolerant genes 18 2) 404 "House-22
keeping" genes, involved in crucial roles in cell maintenance 19 3) 1,359 genes with functional de novo 23 mutations from the healthy control dataset ( Supplementary Table 14 ); 4) 444 Well-known dominant ID 24 genes ( Supplementary Table 4 ). 25
Gene set based evaluation of pLI 26
We evaluated the pLI by computing the expected median pLI for each gene set based on randomly 27
drawing n pLI values from the complete set of 18,226 pLI annotated genes and calculate the median 28 (where n is the number of genes in the gene set). By repeating this random sampling process 100.000 29 times, we can compute the likelihood of the observed median pLI to the expected median pLI by 30 calculating the empirical p-value: 31
where m is the median pLI of one simulation, m observed is the observed median pLI and N is the total 32 number of performed simulations (N=100.000). Based on the simulations we identified a significant 33 lower (Observed 9.33x10 -9 vs. expected 0.03; empirical p-value: <1x10 -5 ) median pLI for the loss-of-34 function tolerant (LoFT) genes which is in line with the LoF tolerant nature of this gene set. For the 35 healthy control set the observed median pLI matched the expected median pLI (Observed 0.03 vs. 1 expected 0.03; empirical p-value: 0.31). For the "house-keeping" and dominant ID gene sets the 2 observed median pLI is significantly higher than the expected median pLI (Observed: 0.87 vs. expected: 3 0.03; empirical p-value <1x10 -5 ; Observed: 0.95 vs. expected: 0.03; empirical p-value <1x10 -5 , 4 respectively). The median pLI of the "house-keeping" gene approximates (median pLI = 0.87) and the 5 dominant ID gene set (median pLI = 0.95) surpasses the extremely LoF intolerant threshold of 0.9 which 6 is in line with the LoF intolerant nature for of "house-keeping" and dominant ID genes (Supplementary 7 Figure 12 ). 8
The set of ten novel candidate ID genes has a median pLI of 0.99 (Observed 0.99 vs. expected 0.05; 9 empirical p-value <1x10 -5 ) which is, as observed for the dominant ID genes, above the extremely LoF 10 gene threshold of 0.9 (Supplementary Figure 8) . For the 21 dominant 'missense only' genes (with at 11 least 3 missense mutations in the absence of LoF mutations) we observe the highest median pLI of 12 0.9999 (Empirical p-value <1x10 -5 ) illustrating that those known and novel candidate dominant ID genes 13 that harbor only missense variants are among the most LoF intolerant ID genes (Supplementary Figure  14  8 ). 15
Attributing Residual Variation Intolerance Score (RVIS) for all genes 16
In addition, the Residual Variation Intolerance Score (RVIS) were assessed for the same gene sets as for 17 the aforementioned pLI. The RVIS ranks genes based on whether they have more or less common 18 functional genetic variation relative to the genome-wide expectation. The initial RVIS gene scores were 19 computed based on the NHLBI-ESP6500 data set 20 and recently recomputed based on the ExAC v0. 3 20 dataset (http://genic-intolerance.org/). The genes from our study were annotated with the RVIS scores 21
based on ExAC ( Supplementary Table 8 ). 22 RVIS scores for gene sets were compared in the same way as for the pLI (Supplementary Figure 13) . 23 Again, we found the set of ten novel candidate ID genes to be significantly more intolerant than any 24 random set of genes found (empirical p-value = 4.60x10 -4 ), similar to the known dominant ID genes 25 (Supplementary Figure 13) . For the 21 dominant 'missense only' genes we again observe the lowest 26 median RVIS of 3.56 (Empirical p-value <1x10 -5 ; Supplementary Figure 13 ). 27 28
Estimating clustering of de novo mutations 29
The spatial distribution of missense, frame-shifts and nonsense DNMs were analyzed for clustering 30 within the respective gene they occurred based on 100,000 simulations. The locations of observed 31
DNMs were randomly sampled over the coding exons of the gene and the distances (in base pairs) 32 between the mutations were normalized for the total coding size of the respective gene. The geometric 33 mean (the n th root of the product of n numbers) of all mutation distances between the DNMs was taken 34 as a measure of clustering. A pseudo count (adding one to all distances and one to the gene size) was 35 applied to avoid a mean distance of 0 when there are identical mutations and ignoring the distances to 1 the remaining DNMs. 2
Based on the prior distance distribution of the 100,000 simulations, a gene-based empirical probability 3 of the observed distance was computed for dominant ID genes with 3 or more DNMs (n=64 genes) in 4 the ID set of 2,104 trios. A total of 21 genes contained only missense mutations ("missense only" group) 5 and 43 genes contained frame-shift, nonsense or a combination of frame-shift, nonsense and missense 6
DNMs ("LoF + Functional" group). In 21 genes of the "missense only" group five genes had an empirical 7 probability below the significant threshold of 0.05/64, whereas only one of the 43 "LoF + Functional" 8 genes had a empirical probability below the significant threshold ( Supplementary Table 9 ). Fisher's 9
exact test was used to compute the statistical significance. 10
Clinical evaluation of selected patients 11
All patients were referred by clinical geneticists for diagnostic evaluation and overall patient 12
characteristics were comparable to a previously published cohort 13 . To confirm the identification of the 13 novel candidate ID genes, we compared the phenotypes of individuals with a DNM in any one of the 10 14 novel candidate genes and two genes (SLC6A1 and TCF7L2) significantly enriched in the 15 neurodevelopmental cohort. Comparison of phenotypes was only possible for 8/12 genes in which at 16 least two individuals with ID were in the RUMC cohort (7/10 novel candidate ID genes, and 1/2 novel 17 candidate NDD genes). Detailed clinical information of other published individuals is mostly not 18 available. A table listing these clinical details is provided in Supplementary Table 7 . For TLK2 and SETD2 19 a more detailed phenotypic comparison was performed (see case reports below). 20 21 
19.
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Supplementary Text 1
Case reports of individuals with DNMs in selected novel candidate ID genes 2 TLK2 3
Patient 17 4
This male is the second of three children of consanguineous parents of Turkish ancestry. His father had 5 learning difficulties and was illiterate. He was born after 40+3 weeks of gestation with a birth weight of 6 3415 gram (0 SD), length of 50 cm (-2 SD) and head circumference of 35 cm (0 SD). Delivery was 7
uncomplicated. Both motor and language development were delayed. He started walking at the age of 2 8
years. At the age of 20 years, psychological assessment revealed a TIQ level of 56 (WISC-III). He followed 9 special education as a child, but after finishing this, he was not able to work due to severe psychiatric 10 problems with frequent tantrums and periods of hyperventilation. Several psychiatric medications 11 turned out to be insufficient. Ophthalmologic examination revealed myopia (-2.5/-3.5 dioptre) and 12 strabismus of the left eye. He was treated for oesophagitis and had frequent diarrhea. Because of his 13 delayed development, he was referred to a clinical geneticist. Physical examination at the age of 16 14 years showed a normal height of 171 cm (-0.5 SD, based on normal values for Turkish children 1 and 15 normal weight of 50.3 kg (-0.5 SD). He had facial dysmorphisms including short forehead, upward 16 slanting palpebral fissures, mild epicanthal folds, hypertelorism, ptosis, flat mid-face, thin upper lip and 17
pointed chin. Thoracal kyphosis and scoliosis were noticed. His hands showed contractures of the 18 proximal interphalangeal joints of the fourth fingers and absence of flexion creases of the distal 19 interphalangeal joints of the second till fourth fingers. Previous investigations, comprising of 20 karyotyping, fragile X screening and SNP array analysis were normal. Metabolic screening and brain MRI 21
scan, performed at age 16 years, showed no abnormalities. Using whole exome sequencing, a de novo 22
TLK2 mutation was identified: Chr17(GRCh37):g.60678182G>T; NM_006852.3:c.1720+1G>T (p.(r.spl?)). 23
Patient 439 24
This male patient is the second of two children of nonconsanguineous parents of Dutch ancestry. There 25
were no developmental problems reported in the family. Prenatal ultrasound showed a single umbilical 26 artery. He was born after 40 weeks of gestation with a birth weight of 3170 gram (-1 SD) after an 27 uncomplicated delivery. As neonate, he had feeding difficulties and low weight. His development was 28 delayed. He started walking at the age of 18 months. He spoke the first words at normal age, but further 29 language development was delayed and he speaks with hoarse voice. Psychological assessment at the 30 age of 5 years showed a borderline TIQ level of 80 and at the age of 7.5 years a mild intellectual 31 disability with a TIQ level of 67 (SON-R 6-40). He was recently diagnosed with multiple complex 32 developmental disorders, with severe problems in regulation of emotions and anxiety. Treatment with 33
Abilify and Cipramil has been started to alleviate the symptoms. The boy had severe constipation, 34 requiring laxatives. Physical examination at the age of 7 years showed a short stature, with a height of 35 11.5 cm (-2.5 SD), normal weight of 21 kg (0 SD) and normal head circumference of 50 cm (-1 SD). He 36 had facial dysmorphisms including upward slanting palpebral fissures, blepharophimosis, ptosis, full 37 nasal tip and pointed chin. His hands showed brachydactyly and single flexion crease of the second and 38 third finger. Previous investigations, consisting of fragile X screening and SNP array, were normal. 1
Metabolic screening showed no abnormalities. Using whole exome sequencing a de novo TLK2 mutation 2 was identified: Chr17(GRCh37):g.60689765C>T; NM_006852.3:c.2092C>T (p.(Arg698*)). 3
SETD2 4

Patient 162 5
This male patient is the first child of three children of non-consanguineous parents of Dutch ancestry. 6 There were no developmental problems reported in the family. He was born after 36+4 weeks of 7 gestation which was complicated by maternal hypertension and HELLP syndrome. Delivery was 8 uncomplicated. His birth weight of 2625 gram (-1.5 SD) was normal. There was normal motor 9
development, but delayed development of language, with the first words at the age of 3 year. At the age 10 of 7 years, psychological assessment showed mild ID with TIQ of 54 (WISC-III). As child, he received 11 surgery for bilateral inguinal hernia. He needed glasses to correct myopia (-2/-2.5 dioptre). Physical 12 examination at the age of 11 years showed macrocephaly with a head circumference of 59.5 cm (+4 SD), 13 high-normal height of 164.4 cm (+2 SD) and low-normal weight of 45 kg (-2 SD 
Patient 716 23
This male patient was the second of two children of non-consanguineous parents of Dutch ancestry. His 24 older brother needed special education because of severe behavior problems. Further family history 25 was not contributory. He was born after 40 weeks of gestation with a birth weight of 3000 gram (-1.5 26 SD). Delivery was uncomplicated. In the first year, no problems were noticed, but after his first year, 27 both motor and language development were delayed. He walked the first steps at the age of 19 months. 28
As young child, he was aggressive to other children, but this improved from the age of 8 years. He was 29 referred to a clinical geneticist because of developmental delay, tall stature and macrocephaly. From 30 age 9 years, he eats unrestrained and gains weight. Physical examination at the age of 9 years showed 31 tall stature with height of 162.5 cm (+2.5 SD), macrocephaly with head circumference of 57.8 cm (+3 SD) 32
and normal weight of 55.5 kg (+1.5 SD). He had facial dysmorphisms including high forehead, deep set 33 eyes and downward slanting of palpebral fissures. There was clinodactyly of his second and third toes 34
and he had a mastocytoma on his right leg. Brain MRI at the age of 9 years showed a subarachnoid cyst 35 left temporal. Analysis of growth hormones showed no abnormalities, but hand films revealed advanced 36 carpal and phalangeal bone age of 11 years at the age of 9 years. Previous investigations, consisting of 37 karyotyping, fragile X and Sotos screening were normal. Using family-based whole exome sequencing a 38 de novo mutation in SETD2 was identified: Chr3 (GRCh37) Figure 1 . Overview of the percentage of on target coverage by 10 or more reads. A scatter plot of the percentage of on target coverage by 10 or more reads shown for the 820 samples of the RUMC cohort. In this figure the samples are ordered ascending based on the percentage of on target coverage. The median percentage of 98.9% on target coverage by 10 or more reads of the RUMC cohort is depicted by the black thick line. Figure 6 . Flow chart of cohort construction for statistical analysis. Based on the presence of de novo mutations (DNMs) in 1,537 known ID genes (Supplementary table 4) the patients were divided among two groups for a) the RUMC cohort (820 trios) b) the combined ID cohort (2,104 trios) and c) the neurodevelopmental cohort (6,206 trios) . The group on the left side in the color red indicate the patients with DNMs found in known ID genes. On the right, in color green, is the group of patients without DNMs present in the 1,537 known ID genes. The statistical analysis was performed on the cohort consisting of patients without DNMs in known genes. The number of trios and DNMs present in genes is shown for each group. Figure 7 . SETD2 (Q9BYW2) with de novo mutations in individuals with ID and ASD. Individuals show similar overgrowth phenotype including macrocephaly, tall stature and facial dysmorphisms (Supplemental Case reports). Supplementary Figure 8 . Intolerance to Loss-of-function (LoF) variation for ID genes. The box plots indicate the median pLI (probability LoF intolerant) for the gene sets based on 100,000 simulation (see Online Methods). The red diamonds show the observed median pLI. The closer a pLI is to 1 the more intolerant a gene is to LoF variants. A pLI >= 0.9 is considered as an extremely LoF intolerant set of genes 21 . The genes with at least one functional de novo mutation in healthy control set (Pink box; N=1,359) the observed median pLI matched the expected median pLI (Observed 0.03 vs. expected 0.03; empirical p-value: 0.31). For the set of dominant ID genes (blue box; N=444) and ten novel candidate ID genes (green box) the observed median pLI is significantly higher than the expected median pLI (Observed: 0.87 vs. expected: 0.03; empirical p-value <1x10 -5 ; Observed 0.99 vs. expected 0.05, respectively). For the dominant 'missense only' genes (with at least 3 missense mutations in the absence of LoF mutations; Orange box; N=21) we observe the highest median pLI of 0.9999 of all evaluated gene sets. 
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